Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2020

Magro C, Schwartz Z, Saab J, Hedayat A. Enhanced cutaneous Rock2 expression as a marker of Rho Kinase pathway activation in autoimmune disease and Kohlemeier-Degos disease. Ann Diagn Pathol. 2020;44:151414.

Burkhart DL, Morel KL, Wadosky KM, Labbé DP, Galbo PM, Dalimov Z, et al. Evidence that EZH2 Deregulation is an Actionable Therapeutic Target for Prevention of Prostate Cancer. Cancer Prev Res (Phila). 2020;13(12):979-988.

Schwartz Z, Bender A, Magro CM. Solitary congenital Langerhans cell histiocytoma: A pattern of benign, spontaneous regression in patients with single lesion disease. Pediatr Dermatol. 2020;37(6):1009-1013.

Georgesen C, Magro C. Lymphomatoid papulosis in children and adolescents: A clinical and histopathologic retrospective cohort. Ann Diagn Pathol. 2020;46:151486.

Fox CP, Civallero M, Ko Y-, Manni M, Skrypets T, Pileri S, et al. Survival outcomes of patients with extranodal natural-killer T-cell lymphoma: a prospective cohort study from the international T-cell Project. Lancet Haematol. 2020;7(4):e284-e294.

Del Gaudio I, Sasset L, Di Lorenzo A, Wadsack C. Sphingolipid Signature of Human Feto-Placental Vasculature in Preeclampsia. Int J Mol Sci. 2020;21(3).

Lin LL, Lakomy DS, Chiao EY, Strother RM, Wirth M, Cesarman E, et al. Clinical Trials for Treatment and Prevention of HIV-Associated Malignancies in Sub-Saharan Africa: Building Capacity and Overcoming Barriers. JCO Glob Oncol. 2020;6:1134-1146.

Zanazzi G, Liechty BL, Pendrick D, Krasnozhen-Ratush O, Snuderl M, Allen JC, et al. Diffuse midline glioma with novel, potentially targetable, fusion. Cold Spring Harb Mol Case Stud. 2020;6(5).

Marzio A, Pagano M. Loss of the deubiquitinase OTULIN promotes hepatocellular carcinoma (HCC) in an mTOR-dependent manner. Cell Death Differ. 2020;27(5):1455-1456.

Khorrami M, Prasanna P, Gupta A, Patil P, Velu PD, Thawani R, et al. Changes in CT Radiomic Features Associated with Lymphocyte Distribution Predict Overall Survival and Response to Immunotherapy in Non-Small Cell Lung Cancer. Cancer Immunol Res. 2020;8(1):108-119.